GILEAD SCIENCES, INC（GILD）の決算・業績分析
GILEAD SCIENCES, INCの2025年有価証券報告書をAI分析。売上高$29.4B(+2.4%)。営業利益$10.0B。Health Care。
目次
GILEAD SCIENCES, INCの2025年度 業績サマリー
GILEAD SCIENCES, INC（証券コード: GILD）の2025年度決算・業績分析。売上高は$29.4B（前年比+2.4%）。営業利益は$10.0B（前年比+503.0%）。純利益は$8.5B（前年比+1672.9%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
GILEAD SCIENCES, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Gilead Sciences reported $27.3B in revenue for FY2024, a marginal decline of -0.1% YoY (XBRL).
- Operating income fell sharply by 26.1% YoY to $7.3B (XBRL), driven by impairment charges and R&D investments (10-K).
- Strong cash flow generation: $9.1B operating cash flow and $8.3B free cash flow (XBRL), with $5.1B returned to shareholders via dividends and buybacks (XBRL).
- R&D investment reached $5.0B (XBRL), reflecting ongoing pipeline development (10-K).
GILEAD SCIENCES, INCの売上高変化の要因
- •Total revenue for FY2024 was $27.3B, a -0.1% YoY decline (XBRL). Growth drivers included HIV, Oncology, and Liver Disease product sales, though segment-specific revenue breakdowns are unavailable (10-K). Over the past five years, revenue grew at a CAGR of +4.2% (XBRL), but operating income CAGR declined by -1.5% (XBRL). The company’s revenue trajectory shows resilience despite challenges in HIV product sales and oncology program adjustments (10-K).
GILEAD SCIENCES, INCの営業利益変化の要因
- •Operating income fell 26.1% YoY to $7.3B (XBRL), with operating margin at 26.9% (XBRL). Net income declined 26.2% YoY to $4.6B (XBRL), with a net margin of 16.8% (XBRL). EBITDA increased by 28.1% (XBRL), reflecting cost management and operational efficiency. The decline in profitability was attributed to impairment charges, R&D investments, and strategic shifts in oncology programs (10-K).
GILEAD SCIENCES, INCの事業リスクと対応
HIV product sales risk: Revenue heavily depends on HIV treatments, which could decline due to competition or shifts in treatment paradigms (10-K).
Cell therapy challenges: Manufacturing, side effect management, and physician acceptance pose risks for CAR T-cell therapies (10-K).
Third-party logistics risks: Reliance on apheresis centers and vendors for cell therapy logistics may cause disruptions (10-K).
Manufacturing capacity risks: In-house facilities may struggle to scale production for growing demand (10-K).
Product innovation risks: Failure to develop new products or expand indications could harm business growth (10-K).
Regulatory risks: FDA’s 2024 class labeling change for CAR T-cell therapies (boxed warning on secondary malignancies) (10-K).
GILEAD SCIENCES, INCの今後の見通し・業績予想
GILEAD SCIENCES, INCの事業内容
Gilead Sciences is a biopharmaceutical company focused on developing and selling innovative medicines for life-threatening diseases, including HIV, viral hepatitis, cancer, and inflammation (10-K). Its revenue model relies on product sales, including branded medications and collaboration revenue sharing (e.g., Symtuza with Janssen) (10-K). Key products include HIV treatments (Biktarvy, Genvoya, Descovy, Truvada) and liver disease medications (Epclusa, Vemlidy, Harvoni), with additional segments in oncology, inflammation, and collaboration products (10-K). Competitive advantages include first-in-class therapies, extensive R&D investment ($5.0B in FY2024), and a diverse product portfolio addressing unmet medical needs (10-K).
GILEAD SCIENCES, INCのAI業績分析レポート（2024年度）
Gilead Sciences, Inc. (GILD) FY2024 Annual Report Analysis
Highlights
Business Overview
Gilead Sciences is a biopharmaceutical company focused on developing and selling innovative medicines for life-threatening diseases, including HIV, viral hepatitis, cancer, and inflammation (10-K). Its revenue model relies on product sales, including branded medications and collaboration revenue sharing (e.g., Symtuza with Janssen) (10-K). Key products include HIV treatments (Biktarvy, Genvoya, Descovy, Truvada) and liver disease medications (Epclusa, Vemlidy, Harvoni), with additional segments in oncology, inflammation, and collaboration products (10-K). Competitive advantages include first-in-class therapies, extensive R&D investment ($5.0B in FY2024), and a diverse product portfolio addressing unmet medical needs (10-K).
Revenue Analysis
Total revenue for FY2024 was $27.3B, a -0.1% YoY decline (XBRL). Growth drivers included HIV, Oncology, and Liver Disease product sales, though segment-specific revenue breakdowns are unavailable (10-K). Over the past five years, revenue grew at a CAGR of +4.2% (XBRL), but operating income CAGR declined by -1.5% (XBRL). The company’s revenue trajectory shows resilience despite challenges in HIV product sales and oncology program adjustments (10-K).
Profitability Analysis
Operating income fell 26.1% YoY to $7.3B (XBRL), with operating margin at 26.9% (XBRL). Net income declined 26.2% YoY to $4.6B (XBRL), with a net margin of 16.8% (XBRL). EBITDA increased by 28.1% (XBRL), reflecting cost management and operational efficiency. The decline in profitability was attributed to impairment charges, R&D investments, and strategic shifts in oncology programs (10-K).
Balance Sheet Analysis
Equity ratio stood at 36.8% (XBRL), with total long-term debt of $23.2B (XBRL). Current ratio was 1.43x (XBRL), indicating moderate liquidity. ROE was 20.1% (XBRL), and ROA was 7.4% (XBRL). Liquidity details (cash, credit facilities) are not disclosed in the XBRL or 10-K (N/A).
Cash Flow Analysis
Operating cash flow was $9.1B (XBRL), exceeding net income due to non-cash expenses and working capital management (CCC: 142 days) (XBRL). Free cash flow was $8.3B (XBRL), calculated as operating cash flow ($9.1B) minus CapEx ($728M) (XBRL). Investing activities included $728M in CapEx (XBRL) and a $4.3B acquisition of CymaBay Therapeutics (10-K). Financing activities totaled -$6.5B (XBRL), with $3.7B in dividends and $1.4B in share repurchases (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 142 days (XBRL), with receivables days at 62, inventory days at 115, and payables days at 36 (XBRL).
Risks
Outlook
Management expects growth in HIV and oncology therapies, driven by R&D investments and strategic shifts like the CymaBay acquisition and Trodelvy program adjustments (10-K). Key trends include continued focus on innovation, expansion of indications, and navigating reimbursement pressures from government agencies and third parties (10-K).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 22.1B | 22.4B | 24.7B | 27.3B | 27.3B | 27.1B |
| Operating Income | 8.2B | 4.3B | 4.1B | 9.9B | 7.3B | 7.6B |
| Net Income | 5.5B | 5.4B | 123M | 6.2B | 4.6B | 5.7B |
| Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 59.0B |
| Total Equity | 22.5B | 18.2B | 21.1B | 21.2B | 22.8B | 19.3B |
| Operating Cash Flow | 8.4B | 9.1B | 8.2B | 11.4B | 9.1B | 8.0B |
Health Careの企業一覧
GILEAD SCIENCES, INCと同じ「Health Care」セクターの企業